PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma

被引:0
作者
Christiaan Schiepers
Jean-Emmanuel Filmont
Johannes Czernin
机构
[1] University of California,Ahmanson Biological Imaging Center, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2003年 / 30卷
关键词
Lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; Primary staging; Metabolic Imaging; FDG; PET;
D O I
暂无
中图分类号
学科分类号
摘要
Metabolic or molecular imaging with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has emerged as a powerful imaging modality for diagnosis, staging, and therapy monitoring of a variety of cancers. The accuracy of FDG-PET as an imaging tool for the primary staging of lymphoma suffers from the absence of a reference criterion to which all imaging modalities can be compared. For ethical reasons, pathological diagnosis is usually not possible for all of the lesions and abnormalities found. In this article, the current state of the art for staging of primary lymphoma is reviewed and the implications for staging and the impact on patient management discussed. Whole-body PET using FDG is superior to conventional staging, i.e., physical examination, laboratory tests, plain radiography, and CT, by 10–20%. The sensitivity of FDG-PET varies for different regions of the body and appears lowest for infradiaphragmatic disease involvement. Staging with metabolic imaging leads in 10–40% of patients to a change in clinical stage. Highly variable results have been reported on whether up- or downstaging of lymphoma with PET leads to changes in the therapeutic approach for primary lymphoma.
引用
收藏
页码:S82 / S88
相关论文
共 46 条
[1]  
Jemal M(2002)Magnetic resonance imaging and67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study CA Cancer J Clin 52 23-224
[2]  
Hoh C(1997)undefined Semin Nucl Med 27 94-undefined
[3]  
Delbeke M(1999)undefined J Nucl Med 40 591-undefined
[4]  
Okada G(1991)undefined J Nucl Med 32 686-undefined
[5]  
Okada F(1994)undefined Ann Nucl Med 8 187-undefined
[6]  
Okada E(1992)undefined J Nucl Med 33 325-undefined
[7]  
Leskinen-Kallio undefined(1991)undefined J Nucl Med 32 1211-undefined
[8]  
Front undefined(1990)undefined Radiology 175 515-undefined
[9]  
Delcambre undefined(2000)undefined Eur J Nucl Med 27 176-undefined
[10]  
Bekerman undefined(1984)undefined Semin Nucl Med 14 296-undefined